BVCF - Key Persons
Mr. Zhuo joined BVCF in 2008. As head of BVCF's Beijing office, Mr. Zhuo is responsible for deal sourcing and execution in the Beijing and Northern China areas. He is also actively involved in developing BVCF's relations and cooperation with the Chinese government.
He has over 20 years of experience in the life sciences industry in China, serving in the roles of Representative Officer to China of the World Health Organization, Vice Director of the Technology Incubation Center at Beijing Zhongguancun Shangdi Biomedicine Industrial Park, Senior Manager of Hangzhou SETS Biopharmaceutical Company and International Biopharmaceutical Group, founder of Beijing GSETS Biopharmaceutical Company, and consultant for Zhongguancun Daxing Biomedical Park.
Mr. Zhuo earned his Bachelor of Science Degree in Pharmacology at Sichuan Medical University and earned his EMBA from University of North Carolina at Chapel Hill.
Dr. Shuo Kang became a member of BVCF in 2021. After finishing his post-doctoral training at Feinberg School of Medicine in the Northwestern University, Dr. Kang joined a biotech start-up and gained experience in target validation, preclinical pharmacology/efficacy studies for developing new drugs.
Dr. Zhi Yang - CEO, Chairman, Founder
Job Titles:
- Chairman
- Founder
- Managing Partner
Dr. Yang founded BVCF in 2005. He has over 20 years of China and U.S. life sciences investment experience as a private equity investor, senior executive, entrepreneur, and scientific inventor. As private equity investor, he has built portfolios of over 30 companies, with 8 exits (4 IPO and 4 acquisitions). As entrepreneur, he co-founded 7 companies, 6 of which continue to conduct business and grow. As scientist, he was the principal inventor of more than 10 U.S. and international patents, which have been documented to have earned MNCs over $250 million. He was a senior fellow and faculty member at Rockefeller University and is now an advisor to the China Health and Medical Development Foundation, under China Ministry of Health. Dr. Yang earned his PhD in Molecular Biology and Biochemistry at Harvard University as a fellow of CUSBEA first class, the first group of mainland Chinese biology scholars selected to be brought to the U.S. after China opened its doors in 1979.
In 2005, Dr. Zhi Yang founded BioVeda China Fund (BVCF) after returning to China from the U.S. BVCF was the first US dollar fund that focused on life sciences and healthcare in China.
Ms. Zhao joined BVCF in 2007. She provides general administrative support and has over 10 years of experience in office administration. Prior to joining BVCF, she worked for Ariba International and JW Marriot.
Ms. Zhao earned her Bachelor of Science Degree in Psychology at Shanghai Normal University.
He holds an M.B.A. from China Europe International Business School.
Job Titles:
- Finance Manager
- in 2012 As Finance Manager
Mr. Geng joined BVCF in 2012 as Finance Manager. He has over 20 years of experience in accounting, and his responsibilities focus on the management of finance, compliance, reporting and operations for BVCF portfolio companies.
He has assumed the position of CFO at BVCF portfolio company, Nexchem Pharmaceuticals. Prior to joining BVCF, Kevin was Financial Manager with Shanghai Huatong Investment Group, where he was in charge of annual budgeting as well as financial due diligence for prospective investee companies.
He earned his Bachelor's Degree in Accounting at Shanghai University of Finance and Economics.
Ms. Chen joined BVCF in 2007. She is heavily involved in BVCF operations, financial reporting to investors, and works closely with Senior Investment Team on financial due diligence of potential investments, and financial valuation of portfolio companies post investment. She also manages BVCF back office operations; administrative, financial and risk management operations, including development and monitoring of control systems.
Prior to that, she had five years of financial auditing experience with Price Waterhouse Coopers, managing the audits for financial institutions.
Ms. Chen earned her Bachelor of Science Degree in International Accounting at Shanghai University of Finance & Economics.
Ms. Zhao joined BVCF in 2006. She has over 15 years of experience in China life sciences private equity, expertise in domestic deal execution and broad network of finance professionals. She has actively invloved in Cathay Biotech, CITIC Pharma, Novast Laboratories, Biocytogen and lead in Cargen Therapeutics, Drugfarm, Ribo, etc. She has BS Economics and MS Economics from Fudan University.
Dr. Li joined BVCF as a Partner in 2007. He has over 20 years of China and U.S. life sciences expertise in private equity and corporate investment, as well as entrepreneurship, operational management, and scientific discovery. Prior to joining BVCF, he was responsible for H&Q Asia Pacific's life sciences investment and management in the Asia Pacific region (through its vehicle, Sinogen.) Before that, he served as a founding scientist of Human Genome Sciences, a human genomics pioneering company later on acquired by GSK for $3 billion. Dr. Li was appointed as an overseas member of the China National Committee for New Drug Development in 1996. He served on the board of the Sino-American Pharmaceutical Association (SAPA). Dr. Li holds numerous patents and earned his PhD in Molecular Biology and Bio-chemistry at Harvard University, as a fellow of CUSBEA's fourth class.
Job Titles:
- Executive Assistant to the Chairman
Ms. Li joined BVCF in 2005. She is responsible for administrative support for Dr. Yang's activities and office management of BVCF. She has over 20 years of experience in office administration, business registration, finance and internal management process.
Prior to joining BVCF, Ms. Li worked for Mingyuan Chemical and Xingtehao, a subsidiary of listed company, Delong Group.
Vanessa Huang joined BVCF as a General Partner in 2017. Vanessa has over 20 years of experience in healthcare and investment banking in the U.S. and Hong Kong. Prior to joining BVCF, Vanessa was Head of Emerging Asia Healthcare Investment Banking at J.P. Morgan. Vanessa has biotech industry experience at Amgen, Inc. and holds an MBA from The Wharton School, University of Pennsylvania.
Mr. Wang joined BVCF in 2020. Mr. Wang is responsible for fund raising, deal sourcing and investment-related topics.
He has multiple years of experience in the PE industry and entrepreneurship in China Prior to joining BVCF, he worked at NetEase Beijing Office.
Mr. Wang earned his Bachelor of Business Administration in Management School at Sun Yet-sen University and earned his master degree in Finance from University of Chinese Academy of Sciences.
Mr. Wang served as a Managing Director of Rothschild China, where he led several large cross-border merger and acquisition ("M&A") transactions. From 2014 to 2015, Mr. Wang served as a Vice President for Royal DSM N.V, a global health, nutrition, and materials company headquartered in the Netherlands. Previously, Mr. Wang served as a Managing Director for HSBC China, where he executed multiple scale cross-border M&A transactions and initial public offerings, from 2010 to 2014. From 2009 to 2010, Mr. Wang served as a Vice President and Head of Global Investment and M&A for Sinochem Group. Previously, Mr. Wang served in various capacities for Lanxess from 2003 to 2008, including as President and Founding CEO of Lanxess China and as Managing Director of Lanxess Hong Kong. From 1996 to 2003, Mr. Wang served as a Director and Head of Strategy for Bayer China.
Mr. Wang holds a Bachelor degree in Computer Science from Fudan University and a Masters in Business Administration from the Executive program at China Europe International Business School.
Huang Yunlong joined BVCF as Managing Director in 2020. Mr. Huang has over 20 years of experience in healthcare industry in mainland China and Hong Kong. Prior to joining BVCF, Mr. Huang was the general manager of Shijiazhuang Sifang Pharmaceutical. Prior to that, he was the CFO of China Resources Double Crane Pharmaceutical and Shiyao Holding Group, in charge of the strategy，operation and financial management.